Épisode 25 : Étude CREDENCE

Diffusé le 25 mai 2019

Dans cette 25e baladodiffusion, les Drs Gabriel Huard et Luc Lanthier discutent de l’effet d’un inhibiteur de la SGLT2, la canagliflozine sur le pronostic rénal des patients avec néphropathie diabétique, en plus de réviser la littérature médicale d’avril 2019.

Syllabus de la présentation

Télécharger en mp3

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-306. PubMed PMID: 30990260.

Lanthier, L, Huard, G, Plourde MÉ, Cauchon M. Chez les patients atteints de diabète type 2 et ayant une néphropathie diabétique avec albuminurie, quel est l’effet de la canagliflozine, un inhibiteur des SGLT2, sur le pronostic rénal et cardiovasculaire ? Rev Med Interne 2020;41(1):67-68. PubMed PMID: 31812446

Ingelfinger JR, Rosen CJ. Clinical Credence - SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease.N Engl J Med. 2019;380(24)2371-73. PubMed PMID: 30990261.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57. PubMed PMID: 28605608.

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323-34. PubMed PMID: 27299675.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28. PubMed PMID: 26378978.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-57. PubMedPMID: 30415602.

Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019;170(11):764-69. PubMed PMID: 31060053.

Boulanger JM, Lindsay MP, Gubitz G, Smith EE, Stotts G, Foley N, et al. Canadian Stroke Best Practice Recommendations for Acute Stroke Management: Prehospital, Emergency Department, and Acute Inpatient Stroke Care, 6th Edition, Update 2018. Int J Stroke. 2018;13(9):949-84. PubMed PMID: 30021503.

Comment gérer votre diabète lorsque vous êtes malade ? (lien)

Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261-74. PubMed PMID: 30874766.

Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019;321(15):1466-80. PubMed PMID: 30903796.

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019;380(14):1326-35. PubMed PMID: 30730782.

Arabi YM, Al-Hameed F, Burns KEA, Mehta S, Alsolamy SJ, Alshahrani MS, et al. Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis. N Engl J Med. 2019;380(14):1305-15. PubMed PMID: 30779530.

Wachterman MW et al. One-year mortality after dialysis initiation among older adults. JAMA Intern Med 2019 Apr 22. doi: 10.1001/jamainternmed.2019.0125. PubMed PMID: 31009039.